The Medicines (MDCO) Earning Somewhat Favorable Press Coverage, Analysis Shows
News coverage about The Medicines (NASDAQ:MDCO) has trended somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. The Medicines earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.7712521883331 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Investors Buy Large Volume of The Medicines Call Options (MDCO) (americanbankingnews.com)
- Brokerages Anticipate The Medicines Company (MDCO) Will Announce Quarterly Sales of $20.38 Million (americanbankingnews.com)
- Emmaus Life Sciences Sickle Cell Treatment Receives Positive Opinion on Pediatric Investigation Plan from European Medicines Agency (markets.financialcontent.com)
- Is the Options Market Predicting a Spike in The Medicines Company (MDCO) Stock? (finance.yahoo.com)
- KindredBio Announces Submission of European Medicines Agency Filing for Mirataz™ (prnewswire.com)
A number of equities analysts have recently commented on MDCO shares. Chardan Capital reissued a “buy” rating and issued a $85.00 price target (up previously from $80.00) on shares of The Medicines in a research report on Tuesday, August 29th. Jefferies Group reaffirmed a “buy” rating and issued a $54.00 price target on shares of The Medicines in a research note on Thursday, October 26th. Oppenheimer set a $50.00 price target on The Medicines and gave the company a “hold” rating in a research note on Thursday, October 26th. Guggenheim began coverage on The Medicines in a research note on Monday, October 23rd. They issued a “buy” rating and a $45.00 price target for the company. Finally, Zacks Investment Research cut The Medicines from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $53.67.
The Medicines (NASDAQ MDCO) traded down $0.86 during mid-day trading on Friday, reaching $26.94. The company had a trading volume of 1,212,771 shares, compared to its average volume of 1,270,000. The Medicines has a one year low of $25.40 and a one year high of $55.95. The company has a current ratio of 2.31, a quick ratio of 1.79 and a debt-to-equity ratio of 3.42. The company has a market cap of $1,900.00, a price-to-earnings ratio of -2.94 and a beta of 0.69.
The Medicines (NASDAQ:MDCO) last posted its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The company had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. During the same quarter last year, the company earned ($0.64) EPS. The firm’s revenue for the quarter was down 55.1% on a year-over-year basis. equities research analysts predict that The Medicines will post -8.86 earnings per share for the current year.
In other news, Director Alexander J. Denner bought 170,000 shares of the stock in a transaction dated Wednesday, November 29th. The shares were acquired at an average cost of $30.03 per share, with a total value of $5,105,100.00. Following the purchase, the director now directly owns 6,663 shares in the company, valued at approximately $200,089.89. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Clive Meanwell sold 136,250 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the sale, the chief executive officer now directly owns 587,652 shares in the company, valued at $16,007,640.48. The disclosure for this sale can be found here. Corporate insiders own 8.22% of the company’s stock.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.